Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is a biopharmaceutical royalty company that frequently announces transactions, portfolio updates and financial results, making its news flow particularly relevant for investors following royalty-based business models in healthcare. Founded in 1996, the company describes itself as the largest buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry, with a portfolio of royalties on more than 35 commercial products and numerous development-stage therapies.
News about Royalty Pharma often centers on new royalty acquisitions and funding agreements. Recent press releases have described transactions such as acquiring remaining royalty interests in Roche’s Evrysdi, purchasing a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences, and securing royalty interests in Nuvalent’s neladalkib and zidesamtinib. The company also reports synthetic royalty funding agreements, including a deal with Denali Therapeutics based on future net sales of tividenofusp alfa and a funding agreement with Teva for the anti-IL-15 antibody TEV-‘408 for vitiligo and celiac disease.
Royalty Pharma’s news feed additionally includes quarterly financial results, Portfolio Receipts updates, capital deployment figures, debt offerings, dividend declarations and participation in investor conferences. The company highlights clinical and regulatory milestones across its royalty portfolio, such as FDA approvals, Phase 3 trial initiations and pivotal data readouts for therapies like daraxonrasib, litifilimab, pelacarsen and other late-stage candidates.
Investors and observers who follow RPRX news can use these updates to track how the royalty portfolio is evolving, which therapeutic areas are gaining exposure, and how capital is being allocated across approved and investigational products. Regular news also provides insight into Royalty Pharma’s views on the royalty funding market, its use of non-GAAP liquidity measures, and its approach to shareholder returns through dividends and share repurchases.
Royalty Pharma (Nasdaq: RPRX) launched the Royalty Pharma Translational Prize, a new annual award to recognize translational medicine breakthroughs.
The Prize includes a $1 million award distributed among one or more established scientists; nominations open summer 2026 and the first laureate will be recognized in spring 2027 at the ABI conference.
Royalty Pharma (Nasdaq: RPRX) announced a $0.235 dividend per Class A ordinary share for Q2 2026. The dividend is payable on June 10, 2026 to shareholders of record at the close of business on May 15, 2026.
Royalty Pharma (Nasdaq: RPRX) will report first quarter 2026 financial results on Wednesday, May 6, 2026 before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time the same day.
Investors can find conference call details and access the live webcast via the company’s Investors events page. A replay will be archived on the website for at least 30 days.
Royalty Pharma (Nasdaq: RPRX) announced a research and development co-funding agreement with Johnson & Johnson totaling $500 million across 2026 and 2027 to advance JNJ-4804, an investigational co-antibody targeting IL-23 and TNF for chronic immune-mediated diseases.
The collaboration funds clinical development of JNJ-4804 and aligns Royalty Pharma with a major immunology partner while advisors Goodwin Procter served as legal counsel.
Royalty Pharma (Nasdaq: RPRX) appointed Lucas Glass as Head of Artificial Intelligence, effective April 2026.
The company said Glass will lead development and implementation of AI capabilities to support royalty evaluation, intelligent automation, advanced analytics and AI-driven decision support, drawing on more than a decade of life‑sciences AI and data experience and prior leadership at IQVIA.
Royalty Pharma (Nasdaq: RPRX) announced expansion of its leadership team, naming Greg Butz as Executive Vice President, Partnering & Investments, effective June 2026. The company also appointed Chris Hite as Chairman, Partnering & Investments and referenced Ken Sun's earlier addition as Head of Asia.
The hires aim to strengthen global origination and execution of royalty transactions, leveraging Butz's two decades of healthcare investment banking experience and Hite's relationship network.
Royalty Pharma (Nasdaq: RPRX) appointed Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Based in Hong Kong, he will lead the company’s royalty business across Asia and expand Royalty Pharma’s global platform.
The appointment follows significant regional deal flow: out‑licensing of Chinese medicines topped $130 billion in 2025, up from about $14 billion in 2021, creating a growing market opportunity for royalty‑based funding.
Royalty Pharma (Nasdaq: RPRX) agreed to provide $250 million to Zymeworks (Nasdaq: ZYME) via a non‑recourse royalty‑backed note secured by 30% of worldwide tiered royalties on Ziihera until repayment.
Repayment ends when Royalty Pharma receives 1.65x the note by Dec 31, 2033, or 1.925x thereafter; Zymeworks retains 70% royalties and all milestone payments up to $1.5 billion potential remaining. Proceeds fund share repurchases, potential acquisitions, and cash runway beyond 2028.
Royalty Pharma (Nasdaq: RPRX) will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET. According to the company, the session will be webcast and archived for at least thirty days.
Investors can access the live webcast and archived replay via the company’s Events page.
Royalty Pharma (Nasdaq: RPRX) reported Q4 2025 Portfolio Receipts of $874 million and full‑year 2025 Portfolio Receipts of $3,254 million, growth of 18% Q4 and 16% FY. Net cash provided by operations was $827 million in Q4 and $2,490 million for FY 2025.
The company deployed $2.6 billion on royalty transactions in 2025, repurchased 37 million Class A shares for $1.2 billion, and raised the quarterly dividend 7% to $0.235 per share. Full‑year 2026 Portfolio Receipts guidance is $3,275M–$3,425M.